Respiratory Strategies in COPD Patients With Persistent Hypercapnia Following Exacerbation: A Multicenter, Non-inferiority, Randomized, Crossover Study

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This multicenter, cross-over study aims to investigate the effects of two different respiratory strategies, the use of high flow nasal cannula (NHF) and the use of home mechanic ventilation (HMV), both associated with standard oxygen therapy, in patients with COPD and persistent hypercapnia following a severe acute exacerbation. The purpose is to evaluate whether the clinical benefits, in terms of reduction in PaCO2 levels, resulting from the use of NHF are non-inferior to those obtained from the use of HMV. Partecipants will be randomized at 1:1 ratio into two groups: group 1: will start the respiratory strategy under study (NHF + standard oxygen therapy) as first treatment group 2 will start the control respiratory strategy (HMV + standard oxygen therapy) as first treatment. The study has a crossover design: each patient will undergo treatment with the two different respiratory strategies, NHF and HMV, each lasting for 3 months

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• Age ≥18 years

• Acquisition of informed consent form

• Patients with COPD

• Persistent hypercapnia (PaCO2 \>53 mmHg) 2-4 weeks after an acute hypercapnic exacerbation of COPD requiring NIV.

• pH value \>7.35.

• Chronic hypoxemia (PaO2 \<55mmHg or \<60mmHg if at least one of the following criteria is present: polycythemia, pulmonary hypertension or Chronic Pulmonary Heart Disease, \>30% of sleep time with SpO2 \< 90% measured with a pulse oximeter)

Locations
Other Locations
Italy
Ospedale S Donato
RECRUITING
Arezzo
Bolzano Hospital
RECRUITING
Bolzano
Azienda Ospedaliera Universitaria Policlinico G. Rodolico-Sn Marco
RECRUITING
Catania
ICS Maugeri Spa Società Benefit IRCCS
RECRUITING
Pavia
Azienda Unità Sanitaria Locale
RECRUITING
Piacenza
Contact Information
Primary
Lara Pisani, Prof.ssa
lara.pisani@unibo.it
0512143257
Time Frame
Start Date: 2024-06-30
Estimated Completion Date: 2028-01
Participants
Target number of participants: 31
Treatments
Experimental: Group 1
NHF/LTOT
Active_comparator: Group 2
HMV/LTOT
Sponsors
Collaborators: Fondazione Salvatore Maugeri, Policlinico Universitario, Catania, Azienda Unita Sanitaria Locale di Piacenza, Ospedale San Donato, Azienda Sanitaria dell'Alto Adige
Leads: IRCCS Azienda Ospedaliero-Universitaria di Bologna

This content was sourced from clinicaltrials.gov